Lung cancer is the leading cause of cancer mortality for both men and women in the United States. 1 The overall 5-year survival rate for the disease is only 16%, but patients with resected non-small cell lung cancer (NSCLC) have a considerably better prognosis. 2 Staging is a critical aspect of the diagnostic workup of lung cancer as it infl uences treatment decisions and allows accurate communication about prognosis to patients and their families. Lymph node (LN) status is a key component of the lung cancer staging classifi cation system and a strong determinant of prognosis. 3 According to the seventh edition of the TNM classifi cation, 4 nodal status is categorized as N0 (no regional LN involvement), N1 (involvement of